Inclusion Criteria:

1. Male subjects ≥18 years at the time of providing written informed consent
2. Pathologically confirmed adenocarcinoma of the prostate or other solid tumors
3. For prostate cancer, ongoing therapy with a gonadotropin-releasing hormone agonist orgonist AND serum testosterone level <50 ng/dL at Screening
4. For prostate cancer, prior treatment with at least 2 Food and Drug Administration(FDA) approved treatments for metastatic castration-resistant prostate cancer.
5. Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging(MRI) and/ or bone scan; images obtained within 28 days prior to the start of studydication will be accepted as baseline
6. For prostate cancer, meet the criteria of disease progression according to thedations of the Prostate Cancer Working Group (PCWG) 3 by one of the following
   1. A sequential rise of PSA (second value obtained at a minimum of 1 week later)baseline measurement of at least 2 ng/mL (1 ng/mL is the minimum startingvalue if confirmed rise is only indication of progression)
   2. Radiographic progression (CT/MRI) by Response Evaluation Criteria in Solid Tumors(RECIST v 1.1) criteria
   3. Nuclear scan progression by new lesions

7. For prostate cancer, discontinuation of flutamide or nilutamide, and other non

   steroidal anti-androgens at least 4 weeks prior to the start of study drug;discontinuation of bicalutamide at least 6 weeks prior to start of study drug.

8. Discontinuation of radiotherapy >4 weeks prior
9. Eastern Cooperative Oncology Group performance status of 0 to 1 at Screening
10. Adequate organ function with following blood counts at Screening:
11. Adequate organ function with following Chemistry values at Screening:
12. Life expectancy of at least 6 months at Screening as per Investigator's judgment
13. Willing and able to provide written informed consent for participation in the study,d comply with all protocol requirements and assessments
14. Agrees to use contraception during the Treatment Period plus an additional 120 dayshe last dose of study treatment and must refrain from donating sperm duringhis period.

Exclusion Criteria:

1. History of allergic reactions to any component of the ARX517.
2. Impaired pituitary or adrenal gland function (e.g., Addison's disease, Cushing'syndrome)
3. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start ofudy medication; subjects who are on a stable dose of these medications for at least30 days at the time of starting study drug are eligible
4. Therapy with estrogen within 30 days prior to the start of study drug
5. Use of systemic glucocorticoids equivalent to >10 mg prednisone daily; subjects whohave discontinued or are on reduced daily dose are eligible within 14 days prior tohe start of study drug
6. Use of any medication such as finasteride/dutasteride known to decrease PSA levels(e.g., saw palmetto) within 30 days of start of study drug
7. Have central nervous system (CNS) metastasis, unless the CNS metastasis was treatedwith local therapy and has proven to be stable over the last 2 months prior tog, and not currently requiring ongoing systemic steroid treatment
8. History of other malignancy within the previous 2 years (no longer being activelyd), except basal cell carcinoma
9. Marked baseline prolongation of QT/QTc interval, e.g. repeated demonstrated of a QTcval > 480 milliseconds (ms) (CTCAE grade 1) using Fridericia's QT correctionula. Major surgery within 30 days prior to the start of study drug
10. Blood transfusion within 30 days of Screening
11. Serious and /or persistent infection within 14 days of the start of study drug
12. Treatment with any investigational drug within 4 weeks prior to Day 1 of the study
13. Known seropositive test for human immunodeficiency virus or seropositive test forhepatitis C virus or hepatitis B virus (testing for hepatitis C and hepatitis B is notquired)
14. Prior history of clinically significant lung disease, pneumonitis, or other clinicallygnificant lung disease within 12 months prior to Screening, with the exception ofhat directly attributable to the presence of lung metastases from their underlying.
15. Prior history of clinically significant ocular events, or any current ongoing activeular infections.
16. Major surgery within 30 days prior to the start of the study drug. Poorly controlleddiabetes, hypertension, history of class III or IV heart failure.